Core Viewpoint - Peijia Medical-B (09996.HK) announced that its CEO and Chairman, Dr. Zhang Yi, will start purchasing company shares in the open market from December 1, 2025, with a total expenditure not exceeding HKD 15 million [1] Group 1: Company Actions - The CEO will begin share purchases on December 1, 2025 [1] - The total cost of the share buyback is expected to be no more than HKD 15 million [1] Group 2: Stock Performance - As of December 5, 2025, Peijia Medical-B closed at HKD 5.54, an increase of 0.73% [1] - The trading volume was 1.0137 million shares, with a total transaction value of HKD 5.6187 million [1] Group 3: Analyst Ratings - The stock has a predominant buy rating from investment banks, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for Peijia Medical-B [1] Group 4: Market Position and Financial Metrics - Peijia Medical-B has a market capitalization of HKD 3.693 billion, ranking 11th in the medical device II industry [1] - Key financial metrics include: - ROE: -10.75% (industry average: -4.03%, ranking: 24th) [1] - Market capitalization: HKD 3.693 billion (industry average: HKD 5.177 billion, ranking: 11th) [1] - Revenue: HKD 668 million (industry average: HKD 1.195 billion, ranking: 15th) [1] - Net profit margin: -20.14% (industry average: -16.5%, ranking: 25th) [1] - Gross margin: 70.07% (industry average: 54.89%, ranking: 62nd) [1] - Debt ratio: 23.63% (industry average: 29.03%, ranking: 15th) [1]
沛嘉医疗-B(09996.HK)获董事长张一增持不超过1500万港元公司股份